Pence Brian Wells, Ostermann Jan, Kumar Virender, Whetten Kathryn, Thielman Nathan, Mugavero Michael J
Health Inequalities Program, Center for Health Policy, Terry Sanford Institute of Public Policy, Duke University, Durham, NC 27708, USA.
J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):194-201. doi: 10.1097/QAI.0b013e31815ace7e.
Expanded access to antiretroviral therapy (ART) has produced dramatic reductions in HIV-associated morbidity and mortality. Disparities in access to and benefit from ART have been observed by race, gender, and mental health status, however.
From 2001 to 2002, 611 HIV-positive patients were consecutively recruited from 5 southeastern US states and followed for 3 years. We evaluated demographic and psychosocial predictors of probability of receiving ART among all those eligible for ART (on ART, CD4 <350 cells/mm3 or viral load [VL] >55,000 copies/mL in the year preceding enrollment), time to first ART discontinuation among those on ART, and time to VL >400 copies/mL among those on ART with VL <400 copies/mL at enrollment.
Of 611 participants, 474 consented to medical record abstraction and had known ART status at enrollment; 81% (385 of 474) of all participants and 89% (385 of 435) of ART-eligible participants were receiving ART at enrollment. In multivariable analyses, ART receipt was associated with greater age (adjusted odds ratio = 1.92 per 10 years, 95% confidence interval: 1.23 to 3.01), fewer recent stressful life events (odds ratio = 0.68, 95% confidence interval: 0.51 to 0.92), less alcohol use (odds ratio = 0.64, 95% confidence interval: 0.46 to 0.90), and greater perceived self-efficacy (OR = 2.82, 95% confidence interval: 1.41 to 5.62). No psychosocial characteristics were associated with ART discontinuation or virologic failure. No racial/ethnic or gender disparities were observed in ART receipt; however, minority racial/ethnic groups were faster to discontinue ART (adjusted hazard ratio = 2.44, 95% confidence interval: 1.33 to 4.49) and experience virologic failure (adjusted hazard ratio = 2.01, 95% confidence interval: 1.09 to 3.71).
Patients with unfavorable psychosocial profiles were less likely to be on ART, perhaps attributable to providers' or patients' expectations of readiness. Psychosocial characteristics were not associated with ART discontinuation or virologic failure, however, possibly reflecting the selection process involved in who initiates ART. Racial disparities in ART discontinuation and virologic failure merit further attention.
扩大抗逆转录病毒疗法(ART)的可及性已使与艾滋病病毒(HIV)相关的发病率和死亡率大幅降低。然而,在获取ART以及从ART中获益方面,已观察到种族、性别和心理健康状况存在差异。
2001年至2002年,从美国东南部5个州连续招募了611名HIV阳性患者,并对其进行了3年的随访。我们评估了所有符合ART治疗条件者(在接受ART治疗,入组前一年CD4细胞计数<350个/立方毫米或病毒载量[VL]>55,000拷贝/毫升)接受ART治疗可能性的人口统计学和社会心理预测因素,接受ART治疗者首次停用ART的时间,以及入组时VL<400拷贝/毫升的接受ART治疗者VL>400拷贝/毫升的时间。
611名参与者中,474人同意提取病历并在入组时已知其ART治疗状态;所有参与者中的81%(474人中的385人)以及符合ART治疗条件的参与者中的89%(435人中的385人)在入组时正在接受ART治疗。在多变量分析中,接受ART治疗与年龄较大(每10岁调整后的优势比= /1.92,95%置信区间:1.23至3.01)、近期压力性生活事件较少(优势比=0.68,95%置信区间:0.51至0.92)、酒精使用较少(优势比=0.64,95%置信区间:0.46至0.90)以及自我效能感较强(优势比=2.82,95%置信区间:1.41至5.62)相关。没有社会心理特征与停用ART或病毒学失败相关。在接受ART治疗方面未观察到种族/民族或性别差异;然而,少数种族/民族群体停用ART的速度更快(调整后的风险比=2.44,95%置信区间:/1.33至4.49),且经历病毒学失败的情况更多(调整后的风险比=2. /01,95%置信区间:1.09至3.71)。
社会心理状况不佳的患者接受ART治疗的可能性较小,这可能归因于提供者或患者对准备情况的期望。然而,社会心理特征与停用ART或病毒学失败无关,这可能反映了启动ART治疗的选择过程。ART治疗停用和病毒学失败方面的种族差异值得进一步关注。